Clinical Trials Browser

Pancreatic Neoplasms

Locally Advanced Rectal Cancer

Colorectal Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Locally Advanced Low Rectal Adenocarcinoma

Locally Advanced Rectal Cancer

Stomach Neoplasms

Rectal Neoplasms

Pancreatic Neoplasms

Rectal Neoplasms

Stomach Adenocarcinoma

Esophageal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Metastatic Pancreatic Ductal Adenocarcinoma

Locally Recurrent Rectal Cancer

Carcinoma, Hepatocellular, Liver Neoplasms

Cholangiocarcinoma

Locally Advanced Rectal Cancer

Stomach Neoplasms

Locally Advanced Rectal Cancer

Early Low Rectal Cancer

Stomach Neoplasms

Low Rectal Cancer

Colonic Neoplasms, Rectal Neoplasms

Rectal Neoplasms

Pancreatic Neoplasms

Carcinoma, Hepatocellular

Gastrointestinal Stromal Tumors

Pancreatic Adenocarcinoma Metastatic

DMMR Colorectal Cancer

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Rectal Neoplasms

Hyperthermia, Digestive System Neoplasms

Carcinoma, Hepatocellular

Colorectal Cancer Metastatic

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Stomach Neoplasms

Colorectal Neoplasms

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

Pancreatic Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Neoplasm Metastasis, Pancreatic Neoplasms

Clinical Trials

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

TORCH-iTNT

Neo-CD

ROSETTE

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

NLCCRIT-LARC

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

SPARC

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

mRCAT-III

TORCH-G

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

CRIT

SPARKLE-L

PanCAN-SR1

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

CCGLC-001

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

TORCH

TORCH-E

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

mRCAT

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

TORCH-R

CISPD-2

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Epacadostat and Pembrolizumab in Patients With GIST

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

IMPROVE

RAIC

HEAIS001

Ablation Combined With PD-1 in HCC: Phase II Study

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer